◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › C › CRSP

Crispr Therapeutics AG (CRSP) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-21

Crispr Therapeutics AG (CRSP) operates in the BIOTECHNOLOGY industry and is headquartered in Zug, Switzerland. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, CRSP reported $4M in revenue and ($582M) in net income.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

Interactive charts & full statements → Open the CRSP valuation workbench →

CRSP Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Total Revenue$13M$4M$35M$370M$0M$913M$1M$290M$3M$41M$5M$0M$0M
Gross Profit($205M)($229M)($75M)$240M($110M)$913M($269M)$290M$3M($29M)($37M)($12M)($2M)
Gross Margin %-1576.9%-6537.0%-215.0%64.8%-25186.7%100.0%-37369.7%100.0%100.0%-70.3%-717.9%-4990.3%—
Operating Income (EBIT)($532M)($568M)($467M)($223M)($673M)$374M($354M)$47M($159M)($65M)($68M)($26M)($7M)
Operating Margin %-4092.3%-16191.4%-1333.1%-60.2%-154394.7%40.9%-49295.5%16.1%-5087.8%-157.7%-1319.3%-10416.6%—
Net Income($451M)($582M)($366M)($154M)($650M)$378M($349M)$67M($165M)($68M)($23M)($26M)($7M)
Net Margin %-3469.2%-16569.8%-1046.4%-41.5%-149122.7%41.4%-48520.9%23.1%-5281.1%-166.7%-449.3%-10456.7%—
EBITDA($453M)($558M)($343M)($131M)($649M)$391M($345M)$51M($155M)($62M)($14M)($26M)($7M)
Earnings Per Share (EPS)$-4.84$-6.47$-4.34$-1.94$-8.36$4.70$-5.29$1.17$-3.44$-1.71$-1.89$-0.88$-0.23
Shares Outstanding (M)97M90M84M79M78M80M66M57M48M40M12M29M29M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRSP Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$10M$1M$1M$1M$1M$1M$35M$1M
Gross Profit($34M)($49M)($58M)($64M)($49M)($57M)$35M($15M)
Gross Margin %-337.8%-3346.4%-6770.8%-7177.1%-5477.7%-6548.4%100.0%-2550.0%
Operating Income (EBIT)($115M)($130M)($155M)($132M)($133M)($148M)($65M)($110M)
Operating Margin %-1127.5%-8933.3%-17912.5%-14854.8%-14918.3%-17158.8%-184.5%-18294.0%
Net Income($91M)($123M)($131M)($106M)($209M)($136M)($37M)($86M)
Net Margin %-895.3%-8431.5%-15117.3%-11973.1%-23379.9%-15722.1%-106.6%-14276.1%
EBITDA($110M)($118M)($124M)($101M)($203M)($130M)($32M)($80M)
Earnings Per Share (EPS)$-0.94$-1.28$-1.45$-1.17$-2.40$-1.58$-0.44$-1.01
Shares Outstanding (M)97M96M90M91M87M86M85M85M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRSP Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash from Operations (CFO)($370M)($345M)($143M)($260M)($496M)$539M($238M)$57M($96M)($70M)($55M)$59M($5M)
Capital Expenditures (CapEx)$2M$1M$2M$9M$37M$82M$18M$7M$3M$8M$3M$1M$1M
Free Cash Flow (FCF)($372M)($346M)($145M)($270M)($533M)$457M($257M)$50M($99M)($78M)($58M)$58M($6M)
FCF Margin %-2861.5%-9855.5%-413.4%-72.9%-122231.4%50.1%-35705.7%17.3%-3169.4%-190.0%-1129.5%23592.7%—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRSP Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($83M)($109M)($93M)($85M)($114M)($54M)($50M)($107M)
Capital Expenditures (CapEx)$0M$1M$1M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($85M)($109M)($93M)($85M)($114M)($54M)($50M)($107M)
FCF Margin %-850.0%-7503.5%-10772.0%-9528.5%-12779.9%-6260.5%-143.7%-17796.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRSP Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Total Assets$2.7B$2.3B$2.2B$2.2B$2.2B$2.8B$1.8B$1.1B$489M$271M$345M$159M$2M
Cash & Cash Equivalents$291M$355M$298M$389M$212M$923M$1.2B$944M$457M$240M$316M$156M$1M
Total Liabilities$904M$343M$310M$347M$368M$352M$164M$127M$97M$84M$112M$189M$9M
Total Debt (Short + Long-Term)$605M$19M$17M$16M$16M$12M$11M$8M$35M$44M$60M$77M$76M
Total Shareholders' Equity$1.7B$1.9B$1.9B$1.9B$1.9B$2.4B$1.7B$939M$392M$188M$233M($29M)($7M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRSP viewer.

Other Companies in BIOTECHNOLOGY

← CRSMAll “C” companiesCRSR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.